12 citations
,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
26 citations
,
June 2003 in “Obstetrics and gynecology clinics of North America” More research is needed to understand the long-term benefits of insulin-sensitizing drugs for treating adolescents with PCOS.
July 2023 in “International journal of dermatology, venereology and leprosy sciences” Intradermal injections might work better for common hair loss than other treatments.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
89 citations
,
November 2014 in “International Journal of Nanomedicine” Using nanostructured lipid carriers to deliver spironolactone could improve treatment for hair loss.
January 2026 in “International Journal of Women s Health” A new model helps predict treatment success in girls with early puberty.
Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
8 citations
,
June 2004 in “Journal of Investigative Dermatology” Certain peptides can prevent hair loss in young rats caused by a cancer drug.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
January 2026 in “International Journal of Molecular Sciences” Brimonidine is effective for reducing facial redness in skin conditions and has potential for broader dermatological uses.
January 2025 in “SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital” PRP injections are safe and effective for alopecia areata, but steroids are still the preferred treatment.
August 2018 in “Dermatologic Surgery” 5 citations
,
January 2000 in “Inhalation Toxicology” Aqueous dispersion resin is safe to inhale at levels below 30 mg/m³.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
January 2025 in “SSRN Electronic Journal”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
March 2024 in “Journal of Neuroscience Research” Finasteride may reduce depression and anxiety in female rats and improve brain connectivity.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Higher doses of spironolactone may improve acne in PCOS patients, but side effects are a concern.
2 citations
,
November 1978 in “JAMA” Valproic acid is an effective seizure medication with some temporary side effects.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
4 citations
,
August 2024 in “PLoS ONE” Both injectable contraceptives lower testosterone and SHBG levels, with NET-EN having a greater effect than DMPA-IM.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
August 2025 in “Endokrynologia Polska” February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.